Despite a drop in revenue and a higher net loss, MannKind Corp. beat analysts’ expectations with its earnings report for the first quarter of 2022. MannKind, a Westlake Village-based biotechnology company that develops drugs and treatments for diabetes and pulmonary arterial hypertension, delivered revenue of $11.9 million in the first quarter of 2022, down from…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
